Prof. Heather Wakelee, Stanford University, USA
Prof. Yan Huang, Sun Yat-sen University Cancer Center, China
Prof. Wei Li, Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, China
Host: Prof. Caicun Zhou, Department of Oncology, Shanghai East Hospital, China
Prof. Huang, Prof. Wakelee and Prof. Li discussed whether patients with pathologic complete response (pCR) after preoperative therapy still need adjuvant immunotherapy, as well as the clinical value and current limitations of ctDNA/MRD in guiding treatment decisions in early-stage lung cancer. They also shared their views on future therapeutic directions, including the potential role of ADCs and bispecific antibodies in the neoadjuvant and adjuvant settings.